Axsome Therapeutics' AXS-05 shows promising results in treatment-resistant depression

By Yahoo! Finance | Jul 22, 2024 at 02:00 AM EST

Axsome Therapeutics' AXS-05, a promising treatment for treatment-resistant depression (TRD), achieved primary and secondary endpoints in a Phase II trial. Its novel mechanism of action and potential rapid onset of action position it as a blockbuster drug with significant market potential.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.